BMED vs THNR: Holdings Overlap & Returns
Over the year to Nov 13, 2026, BMED returned +25.4% to THNR's +6.7%; 20% of their weight is in the same names.
- Return gap
- +18.7 pts1 year to Nov 13, 2026: BMED ahead, total return
- Fee gap
- 0.04 ptsA year: BMED 0.55%, THNR 0.59%, per filings dated Nov 21, 2025 and Jan 28, 2026
- Overlap
- 20%Share of the two books held in common, holdings dated Nov 12, 2026 and Nov 13, 2026
- Net flow
- $0k / −$791kBMED / THNR, Oct 13, 2026 to Nov 12, 2026, daily basis
Compare two other funds
Growth of 100
Drawn from the numbers on this page. Growth of 100, both funds, distributions reinvested
BMED +25.4%, THNR +6.7%: BMED +18.7 pts ahead, 1 year, Nov 13, 2025 to Nov 13, 2026.
ShareUse this comparison
Cost to trade
Hypothetical. A $10,000 order in BMED costs about $11.50 one way and $23.00 in and out, at a median spread of 0.23%. The 0.23% spread is BMED’s 30-day median, from iShares (fund page).
Fees over time
Hypothetical. $10,000 in THNR for 10 years at 0.59% a year costs about $972 in fees and lost growth; BMED at 0.55% would cost $908. Assumes 6% a year before fees, a sample rate, not a forecast.
How each fund moved
58% of BMED's weight is in S&P 500 companies and 42% is outside the index. Holdings as of Nov 12, 2026.
46% of THNR's weight is in S&P 500 companies and 54% is outside the index. Holdings as of Nov 13, 2026.
Key numbers
BMED costs 0.04 points a year less; their one-year returns differ by 18.7 points; BMED is 2.9 times larger.
Pair scorecard
Open the table
Points (pts) are percentage points.
| Total return, 1 year | +25.4% | +6.7% |
|---|---|---|
| Below its all-time high | 6.3%, high on Aug 25, 2026 | |
| What it tracks | Healthcare innovation and GLP-1 | Healthcare innovation and GLP-1 |
| Expense ratio | 0.55% | 0.59% |
| Net assets, as of Nov 12, 2026 | $15m | $5.2m |
| Holdings in common | 20% |
The numbers behind it
Net assets: $15m on Nov 13, 2026 for iShares Health Innovation Active ETF, and $5.2m on Nov 12, 2026 for Amplify Weight Loss Drug & Treatment ETF.
Holdings in common uses holdings dated Nov 12, 2026 and Nov 13, 2026.
What they share
By the books each fund has filed, BMED and THNR hold 20% of their money in the same securities at the same weight. Holdings dated Nov 12, 2026 and Nov 13, 2026.
half
20% in common
Held in common
Show all 6 holdings
| GILEAD SCIENCES | 5.80% | 5.66% |
| ABBVIE | 4.91% | 5.65% |
| MERCK & CO INC | 2.97% | 4.98% |
| ROCHE PS PAR AG | 2.85% | 5.68% |
| AMGEN INC | 2.57% | 6.11% |
| PFIZER | 1.46% | 5.24% |
Only in BMED
Show all 8 holdings
| MODERNA | 5.52% |
| DANAHER | 5.15% |
| THERMO FISHER SCIENTIFIC | 4.33% |
| EDWARDS LIFESCIENCES | 4.25% |
| BIOGEN | 3.70% |
| METTLER-TOLEDO INTERNATIONAL INC | 3.61% |
| IQVIA HOLDINGS INC | 3.58% |
| VERTEX PHARMACEUTICALS | 3.29% |
Only in THNR
Show all 8 holdings
| Eli Lilly & Co | 12.10% |
| Novo Nordisk A/S | 8.89% |
| Regeneron Pharmaceuticals Inc | 6.05% |
| AstraZeneca PLC | 5.79% |
| Chugai Pharmaceutical Co Ltd | 5.17% |
| CSPC Pharmaceutical Group Ltd | 4.44% |
| Viking Therapeutics Inc | 4.43% |
| Innovent Biologics Inc | 4.35% |
Side by side
Open the table
| Fund | iShares Health Innovation Active ETF · Holds 55 stocks in healthcare innovation and GLP-1, 58% of its weight in S&P 500 companies | Amplify Weight Loss Drug & Treatment ETF · Holds 21 stocks in healthcare innovation and GLP-1, 46% of its weight in S&P 500 companies |
| Issuer | iShares | Amplify |
| Theme | Healthcare innovation and GLP-1 | Healthcare innovation and GLP-1 |
| In the S&P 500 | 58.2% | 45.8% |
| Active share vs the S&P 500 | 95.6% | 96.5% |
| In the Nasdaq-100 | 13.8% | 17.8% |
| Holdings | 55 | 21 |
| Top ten, share of the fund | 44.1% | 66.3% |
| Expense ratio | 0.55% | 0.59% |
| Fee for the differing part | 0.58% | 0.61% |
| Total return, 1 year | +25.4% | +6.7% |
| vs its benchmark | not measured | not measured |
| Below its high | −2.7% | −6.3% |
| Net assets, BMED as of Nov 13, 2026 and THNR as of Nov 12, 2026 | $15m | $5.2m |
As of Nov 13, 2026. Source: ETFIQ.
Window by window
Open the table
| 3 months | +12.9% | −0.1% |
|---|---|---|
| 6 months | +33.6% | +7.0% |
| 1 year | +25.4% | +6.7% |
| 3 years | +68.1% | – |
| Since launch (Not the same days: BMED Oct 2020 · THNR May 2024) | +42.8% | +5.6% |
– means no data for this window.
About BMED
By weight, 58% of BMED's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 96%. The top ten holdings are 44% of the fund across 55 positions, as published by its issuer for Nov 12, 2026.
More
Over the year to Nov 13, 2026 the fund returned +25.4% with distributions reinvested.
About THNR
By weight, 46% of THNR's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 96%. The top ten holdings are 66% of the fund across 21 positions, as published by its issuer for Nov 13, 2026.
More
Over the year to Nov 13, 2026 the fund returned +6.7% with distributions reinvested. It sits 6.3% below its all-time high of Aug 25, 2026.
20% of the two portfolios are the same securities at the same weight.
Questions people ask
Do BMED and THNR hold the same stocks?
By their latest filings, 20% of their books are the same securities at the same weight. Overlap is the sum of the smaller weight of every security they share.
Other comparisons
Sources
More
Links are sources, not endorsements. A comparison is not a recommendation.
Copy and cite
Cite this pageCitation, APA and Markdown
ETFIQ, BMED against THNR, data as of Nov 13, 2026. https://etfiq.com/compare/themes/bmed-vs-thnr
ETFIQ. (Nov 13, 2026). BMED against THNR. Retrieved from https://etfiq.com/compare/themes/bmed-vs-thnr
[BMED against THNR (ETFIQ, Nov 13, 2026)](https://etfiq.com/compare/themes/bmed-vs-thnr)
Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.